A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Participants With KRASG12C Mutant Advanced Solid Tumours
This is a study evaluating the efficacy, safety and pharmacokinetics of MK-1084 in participants with advanced solid tumours with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.